← Leaderboards
Daniel A. Pryma
University Of Pennsylvania
$3,728,945
Attributed
$3,728,945
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $678.8K · FY2018–23$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,728,945 · 2
By mechanism
R01$3,728,945 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Constantinos Koumenis$17,144,115
- Amit Maity$4,832,230
- Eric S Diffenderfer$856,922
- Alexander Lin$3,747,658
- Michael David Farwell$4,041,739
Others in their field
Other Emerging Leaders on “Particle Therapy”
- Michael King Schultz · Viewpoint Molecular Targeting, Inc.$7,092,453
- Benjamin E Deverman · Broad Institute, Inc.$5,440,331
- Joseph De Rutte · Partillion Bioscience Corporation$5,082,471
- Benson Edagwa · University Of Nebraska Medical Center$4,982,494
- Hae Lin Jang · University Of California Los Angeles$4,846,597
- Alex De Marco · New York Structural Biology Center$4,736,506
Research focus
Particle TherapyToxic EffectCompanion DiagnosticsNormal Tissue MorphologyResistanceTissuesAlpha ParticlesBiologicalDna RepairNeuroblastomaRadiopharmaceuticalsCancer CellResponseSmall MoleculeCell LineBiodistributionCell NucleusCellsCytotoxicityDepositionDoseMediatingPositron-Emission TomographyTumor
Grant awards (6)
Optimizing theranostic radiopharmaceutical therapy to combat resistance to PARP inhibition in advanced ovarian cancer$678,844
R01 · FY2023 · CA · contact PI
PARP-1 as a novel target for alpha-particle therapy in high-risk Neuroblastoma$577,080
R01 · FY2022 · CA · contact PI
PARP-1 as a novel target for alpha-particle therapy in high-risk Neuroblastoma$595,159
R01 · FY2021 · CA · contact PI
PARP-1 as a novel target for alpha-particle therapy in high-risk Neuroblastoma$615,205
R01 · FY2020 · CA · contact PI
PARP-1 as a novel target for alpha-particle therapy in high-risk Neuroblastoma$610,295
R01 · FY2019 · CA · contact PI
PARP-1 as a novel target for alpha-particle therapy in high-risk Neuroblastoma$652,362
R01 · FY2018 · CA · contact PI